731 Followers on Owler

Beam

Therapeutics develops precision medicines through base editing technology to treat genetic diseases... Read more
OverviewCompetitorsAcquisitionsFundingInvestmentsNews & Insights

Beam

Therapeutics develops precision medicines through base editing technology to treat genetic diseases... Read more
Beam CEO: John Evans

CEO

John Evans

CEO Approval Rating

90/100

2017

PublicIndependent CompanyNASDAQBEAM

Pharmaceuticals & Biotechnology
Biotechnology
2836 NAICS listing

Annual Revenue
$63.5M
Employees
510
Funding
$806.5M
Acquisitions
1
Investments
1

News

Conference Presentation
Mar 11, 2025
Nasdaq
Beam Therapeutics To Present At Barclays Global Healthcare Conference; Webcast At 3:30 PM ET

Beam Competitors

1bluebird bio
2Spark Therapeutics
3Casma
4Intellia
5Sangamo
6CRISPR
7Spotlight Therapeutics
8Homology
9Emmaus
10Genmab
Unlock 20 + competitors

Trending Companies